Aetna to pay $25.5M after denying cancer coverage

Health insurer Aetna must pay $25.5 million to the family of a cancer patient who was denied coverage by the company for treatment.

Jurors stated the insurer acted “recklessly” in its decision to deny coverage for Orrana Cunningham, who had stage 4 nasopharyngeal cancer, CNN reported.

“Her doctors wanted her to receive proton beam therapy, a targeted form of radiation that could pinpoint her tumor without the potential for blindness or other side effects of standard radiation,” CNN reported. “Aetna denied her coverage, calling the therapy investigational and experimental.”

Cunningham died in May 2015, and her family subsequently sued Aetna.

During the case, an Aetna medical director acknowledged handling 80 cases per day, and three medical directors reviewed Cunningham’s case and denied her coverage of proton beam therapy.

Jurors were clear the verdict and award to Cunningham’s family was meant to send a message to Aetna, according to CNN.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.